Unfortunately, there is a very limited range of effective therapies for synovial sarcoma; treatment is so far confined to surgery, radiotherapy and standard chemotherapy with common cytostatics, and several receptor tyrosine kinase inhibitors (sorafenib, pazopanib and bevacizumab). The gene discussed is NTRK1; the disease is synovial sarcoma.